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Abstract
The development of head and neck squamous cell
carcinoma (HNSCC) involves the accumulation of ge-
netic and epigenetic alterations in tumor-suppressor
proteins, together with the persistent activation of
growth-promoting signaling pathways. The activation
of epidermal growth factor receptor (EGFR) is a fre-
quent event in HNSCC. However, EGFR-independent
mechanisms also contribute to the activation of key
intracellular signaling routes, including signal trans-
ducer and activator of transcription-3 (STAT3), nuclear
factor KB (NFKB), and Akt. Indeed, the autocrine ac-
tivation of the gp130 cytokine receptor in HNSCC cells
by tumor-released cytokines, such as IL-6, can result in
the EGFR-independent activation of STAT3. In this
study, we explored the nature of the molecular mech-
anism underlying enhanced IL-6 secretion in HNSCC
cells. We found that HNSCC cells display an increased
activity of the IL-6 promoter, which is dependent on the
presence of an intact NFKB site. Furthermore, NFKB
inhibition downregulated IL-6 gene and protein expres-
sion, and decreased the release of multiple cytokines.
Interestingly, interfering with NFKB function also pre-
vented the autocrine/paracrine activation of STAT3 in
HNSCC cells. These findings demonstrate a cross-talk
between the NFKB and the STAT3 signaling systems,
and support the emerging notion that HNSCC results
from the aberrant activity of a signaling network.
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Introduction
Head and neck squamous cell carcinoma (HNSCC) is the
sixth most common cancer in the world and accounts for
90%ofmalignant neoplasias of the upper respiratory system
[1]. Despite recent advances in the management of lo-
cally advanced HNSCC, the overall survival of patients has
improved only marginally over the past three decades [2]. In
this regard, HNSCC progression often involves the accu-
mulation of a number of genetic and epigenetic alterations
in tumor-suppressor proteins, such as p53, p16, and RB,
concomitant with the aberrant activity of signaling molecules
that drive the unrestricted growth of HNSCC cells [3]. Thus, the
recent development of novel molecular-targeted therapies may
now afford the rational selection of treatment modalities for
HNSCC patients based on specific molecular mechanisms
whose deregulated activity contributes to the initiation, devel-
opment, and metastatic spread of this cancer type.
Roughly 90% of all HNSCC cases exhibit an enhanced
expression of epidermal growth factor receptor (EGFR) [4–6],
and approximately 50% of all advanced HNSCC cases present
an elevated activity of this polypeptide growth factor tyrosine
kinase receptor [7]. This provided the molecular basis for
current efforts aimed at evaluating the clinical activity of EGFR
inhibitors in HNSCC [3,8]. As expected, many of the down-
stream intracellular targets of EGFR, such as signal transducer
and activator of transcription-3 (STAT3), Ras–ERK, and PI3K–
Akt pathways are also often activated in HNSCC [9–11].
However, emerging evidence suggests that both EGFR-
dependent and EGFR-independent mechanisms contribute
to the persistent activation of these key signaling routes in
HNSCC [12,13]. The mechanisms responsible for the EGFR-
independent unregulated function of these signaling routes are
still poorly understood.
Of interest, whereas the activation of EGFR leads to the
rapid tyrosine phosphorylation of STAT3 in tyrosine705 and the
consequent activation of STAT3-dependent gene expression,
we have recently observed that STAT3 tyrosine phosphoryla-
tion and the formation of active STAT3 DNA-binding complexes
are insensitive to the inhibition of EGFR in a large fraction of
HNSCC cell lines [13]. Indeed, 9 of 10 cell lines form a rep-
resentative panel of HNSCC-derived cells showing increased
tyrosine phosphorylation and activity of STAT3, but constitutive
activity of EGFR was present in only 3 of them [13]. In search
for the mechanism responsible for the EGFR-independent ac-
tivation of STAT3 in HNSCC cells, we observed that the
activation of the gp130 cytokine receptor subunit promoted
the phosphorylation of STAT3 in tyrosine705 through the
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activation of intracellular tyrosine kinases of the JAK family
[13]. Surprisingly, the activation of gp130 was found to be
primarily initiated by IL-6, which, on its secretion and release
by HNSCC cells, acts on the IL-6 receptor–gp130 complex
on the cell surface of HNSCC cells in an autocrine fashion
[13]. These findings, together with recently published reports
[14,15], suggest that the persistent activation of STAT3 in
HNSCC can result from the deregulated activity of EGFR or
from the autocrine activation of STAT3 by tumor-released
cytokines in an EGFR-independent fashion.
These observations prompted us to explore the nature of
the molecular mechanism underlying the enhanced pro-
duction and secretion of IL-6 in HNSCC cells. In this study,
we found that overexpression of IL-6 in HNSCC cells involves
increased transcription from the IL-6 promoter, which is
dependent on the presence of an intact nuclear factor nB
(NFnB) response element located 63 to 75 bp upstream of
the IL-6 transcriptional initiation site. Furthermore, inhibition
of NFnB led to a remarkable downregulation of IL-6 gene
and protein expression, concomitant with a decreased re-
lease of other inflammatory cytokines, such as IL-8, IL-10,
granulocyte–macrophage colony-stimulating factor (GM-
CSF), and granulocyte colony-stimulating factor (G-CSF).
Surprisingly, the blockade of NFnB led also to a drastic in-
hibition of the constitutive STAT3 activity in HNSCC cells, as
reflected by the reduced tyrosine phosphorylation of STAT3.
Interestingly, interfering with NFnB function also prevented
the ability of HNSCC cell supernatants to promote the acti-
vation of STAT3 in nontumorigenic epithelial cells in a para-
crine fashion. These findings support the emerging notion
that the aberrant activity of a network of interrelated signal-
ing pathways, rather than a single deregulated biochemical
route, contributes to squamous carcinogenesis. They also
provide an interesting example of a cross-talk between the
NFnB and the STAT3 signaling systems. This cross-talk is
initiated by the release of IL-6 as a consequence of the NFnB-
dependent activation of the IL-6 promoter, and the subse-
quent tyrosine phosphorylation of STAT3 by the autocrine/
paracrine activation of IL-6 receptors in tumor cells.
Materials and Methods
DNA Constructs and Reagents
The dominant-negative IjB A32/36S super-repressor
mutant (kindly provided by Dr. Siebenlist) [16] was cloned
in-frame with a green fluorescent protein (GFP) coding
sequence into the pCEFL expression vector, generating a
pCEFL-GFP-IjB A32/36S plasmid. The lentivirus-encoding
dominant-negative GFP-IjB andGFP genes were generated
using the gateway system from Invitrogen Life Technologies
(Carlsbad, CA) and CSCG-based retroviral vectors, as pre-
viously reported [17,18]. The full-length IL-6 promoter and the
point mutations in the AP-1 and NFnB regulatory elements of
the IL-6 promoter (kindly provided by Dr. Libermann) [19]
were inserted into the KpnI–XhoI sites of the pGL3 luciferase
reporter vector by polymerase chain reaction (PCR), gen-
erating pGL3-IL-6-Luc and its mutants. For report assays,
pGL3-NFjB-Luc, in which luciferase expression is con-
trolled by five NFnB response elements, was also used.
The plasmid pcDNA3-b-galactosidase (BD Biosciences,
San Jose, CA) and pCEFL-GFP were used as controls. Re-
combinant human IL-6 was purchased from PeproTech, Inc.
(Rocky Hill, NJ), and tumor necrosis factor a (TNF-a) was
fromRoche (Indianapolis, IN). Cells were treatedwith a single
dose of IL-6 or TNF-a (10 ng/ml) for 10 minutes.
Cell Lines and Culture Conditions
The HNSCC cell lines HN6, HN12, HN13, and HN30 [20];
HaCaT cells [21]; an immortalized nontumorigenic human
skin keratinocyte cell line; and HEK293TandHEK293FTcells
were cultured in DMEM supplemented with 10% fetal calf
serum, penicillin, and streptomycin. The cells were main-
tained in a 5% CO2-humidified incubator. Stable cell lines
were established by lentiviral infection using CSCG-based
retroviral vectors and 293FT cells as packaging cells. HN13
and HN30 cells were infected with viral supernatants for
24 hours at 37jC in the presence of 8 mg/ml polybrene (hexa-
dimethrine bromide; Sigma, St. Louis, MO). Conditioned
media (CM) from HaCaT and HNSCC cell lines were pre-
pared by incubating subconfluent cultured cells for 24 hours
in DMEM without serum and supplements. Harvested CM
were then filtered through a 0.22-mm low-protein-binding
polyethylsulfonate membrane filter.
Transcription Factor Analysis
Nuclear extracts were prepared using a NE-PER Nuclear
and Cytoplasmic Extraction reagent (Pierce Biotechnology,
Inc.). The double-stranded oligonucleotide consensus se-
quence for NFnB (5V-AGTTGAGGGGACTTTCCCAGGC-3V)
and activating protein 1 (AP1; 5V-CGCTTGATGACTCAGC-
CGGAA-3V) (Santa Cruz Biotechnology, Inc., Santa Cruz
Biotechnology, CA) was labeled with [g32P]ATP using T4
polynucleotide kinase (Invitrogen Life Technologies), puri-
fied, and added to the reactions (20,000 cpm/reaction) for
15 minutes. Complexes were analyzed on nondenaturing
(4.5%) polyacrylamide gels. For supershift assays, 1 mg of
anti-NFnB (C-20) antibody (Santa Cruz Biotechnology, Inc.)
was added to the binding reaction before the addition of a
radiolabeled probe. In separate experiments, to identify the
NFnB subunit proteins in the complex, 2 ml of p65 antibody
was incubated with nuclear proteins before the addition of
the radiolabeled probe to visualize any supershift-retarded
bands in the NFnB complex. Protein–DNA complexes were
separated by electrophoresis on 4% polyacrylamide gel
in Tris–borate–EDTA buffer. NFnB DNA-binding activity
assays were also performed using Trans-AM enzyme-linked
immunosorbent assay (ELISA)–based kit from Active Motif
(Carlsbad, CA), according to the manufacturer’s protocol.
Briefly, cell extracts were incubated in a 96-well plate coated
with an oligonucleotide containing the NFnB consensus-
binding site. Activated transcription factors from extracts
specifically bound to the respective immobilized oligonucleo-
tides were detected using antibodies to NFnB p65, followed
by a secondary antibody conjugated to horseradish peroxi-
dase (HRP) in an ELISA-like assay.
734 Cross-Talk between NFnB and STAT3 in Head and Neck Cancer Squarize et al.
Neoplasia . Vol. 8, No. 9, 2006
IjB Kinase (IKK) Knockdown
Cells were seeded in 24-well or 6-well plates and, on
reaching 70% confluence, the cells were washed twice in
serum-free medium and transfected with 12.5 nM double-
stranded RNA oligonucleotides directed against human IKKa
(NM_001278, SI00605115; Qiagen, Valencia, CA) and with
25 nM against IKKb (NM_001556, SI02777376; Qiagen)
using HyperFect (Qiagen), following the manufacturer’s
instructions.Optimal concentrations of siRNA and time points
were determined by performing a dilution curve of siRNA
for each target, and knockdown was determined by Western
blot analysis. After 72 hours, the cells were treated as
indicated, and nuclear extracts were isolated as described
above. The sequences of the negative siRNA (Qiagen)




Cultured cells were harvested at the times indicated in
each experiment, washed with phosphate-buffered saline,
and lysed in 62.5 mM Tris, 2% sodium dodecyl sulfate (SDS),
and 10% glycerol (SDS sample buffer) with aprotinin, leu-
peptin, pepstatin, and 4-(2-aminoethyl) benzenesulfonyl
fluoride. Cell suspensions were briefly sonicated, and the
protein concentration for each cell lysate was determined
using DC protein assay (Bio-Rad, Hercules, CA). Twenty to
40 mg of total protein from whole cell lysates was loaded onto
each lane for gel electrophoresis. Immunoblotting was per-
formed using 0.1 M Tris (pH 7.5), 0.9% NaCl, 0.05% Tween-
20 with 5% nonfat dry milk as a blocking and antibody-dilution
buffer, and working antisera for STAT3, phospho-STAT3
(pSTAT3)–tyrosine705, IKKa, IKKb, phospho-IKKa/b (Cell
Signaling Technology, Beverly, MA), GFP (Covance, Inc.,
Denver, PA), and tubulin (Santa Cruz Biotechnology, Inc.).
We used 62.5 mM Tris (pH 6.8), 2% SDS, and 100 mM
b-mercaptoethanol to strip probed filters, as indicated in
each experiment.
Immunohistochemistry
Individual paraffin blocks of formalin-fixed tissues from
human squamous cell carcinomas of the oral cavity and
HNSCC tissue arrays containing approximately 460 cases
of oral SCC and normal control tissues were obtained from
the National Institute of Dental and Craniofacial Research,
National Institutes of Health Oral Cancer Tissue Array Initia-
tive (Bethesda, MD) (Molinolo et al., in preparation). Briefly,
individual paraffin-embedded HNSCC tissues from the oral
cavity were arrayed and processed following the standard
methodology of the Tissue Array Research Program (www.
cancer.gov/tarp). Immunohistochemistry was performed as
previously described [22]. In brief, the slides were dewaxed
in xylene and hydrated through graded alcohols. Antigen
retrieval was performed using 10 mM citrate buffer (pH 6.0)
placed in a microwave oven for 20 minutes (2 minutes at
100% power and 18 minutes at 10% power). The slides were
allowed to cool down for 30 minutes at room temperature,
rinsed twice with tris-buffered saline solution (TBST), and
Figure 1. HNSCC cells secrete IL-6 and exhibit enhanced NFjB DNA-
binding activity. (A) IL-6 levels in CM from the indicated cell lines were
measured and presented as bar graphs. Limited amounts of IL-6 were pro-
duced and secreted by HaCaT and HN6; in contrast, high levels were
detected in CM from the HN12, HN13, and HN30 cell lines. The data are
presented as the mean ± SE of triplicate measurements. (B) Levels of
activated NFjB contained in nuclear extracts were assessed by their ability to
bind to a consensus NFjB-binding site oligonucleotide, and an NFjB–DNA
binding complex was revealed by chemiluminescence on incubation with anti-
p65 antiserum followed by a secondary antibody conjugated to HRP. Bar
graphs represent the mean ± SE of quantitative measurements of NFjB in
arbitrary units, which were high in HN12, HN13, and HN30, but not in HaCaT
and HN6, under normal culture conditions. Cell lines were also stimulated
with TNF-a (10 ng/ml for 10 minutes), which stimulates NFjB activation.
HaCaT cells served as positive control. Data are presented as the mean ± SE
of triplicate measurements. (C) EMSA was performed using a 32P-labeled
consensus oligonucleotide containing the sequence for NFjB-binding sites.
Nuclear extracts were harvested from each cell line. Bands (black arrow)
represent shifted protein–DNA complexes, which are found in HN12, HN13,
and HN30, but not in HaCaT and HN6, under regular culture conditions.
HaCaT was also stimulated with TNF-a as a control, thus confirming the
binding and shifting of protein –DNA complexes. Preincubation of nuclear
extracts with anti-NFjB (p65) resulted in the appearance of a slower
migrating (supershifted) band (open arrow), confirming the presence of active
NFjB in protein–DNA complexes.
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incubated in 3% hydrogen peroxide for 30 minutes to quench
the endogenous peroxidase. The sections were then incu-
bated in blocking solution (5% bovine serum albumin) for
1 hour at room temperature, followed by treatment with anti–
IL-6 primary antibody (clone 6708.11; Sigma), NFnB p65 (A)
antibody (Santa Cruz Biotechnology, Inc.), and pSTAT3Y705–
specific antibody (Santa Cruz Biotechnology, Inc.), where
indicated, overnight at 4jC. After washing with TBST, the
slides were incubated with the labeled streptavidin biotin
reagent (LSAB+system HRP; DAKO Corporation, Carpinte-
ria, CA), following the manufacturer’s instructions. The slides
were developed in 3,3-diaminobenzidine (Sigma FASTDAB
tablet; Sigma) and counterstained with Mayer’s hematoxylin.
Images were taken using a SPOT digital camera attached to
a Zeiss Axiophot microscope (Carl Zeiss, Thornwood, NY).
All immunostainings were assessed by two experienced
pathologists. The tumors were classified as positive or
negative (no staining). Statistical analysis was performed
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by two-tailed Fisher’s exact test, and PV .05 was considered
statistically significant.
Reporter Assays
The NFnB and IL-6 promoter reporter constructs con-
taining the firefly luciferase cDNA (0.1–0.3 mg/well) and the
pRL-null normalization construct (0.01–0.03 mg/well) contain-
ing Renilla luciferase from Renilla reniformis were transfected
into HaCaT, HNSCC, and HEK293T cells (40% confluent in
six-well plates). The total amount of plasmid DNA was ad-
justed with pcDNA3-b-galactosidase. When indicated, the
cells were also transfected with pCEFL-p65 plasmid and pre-
treated with 10 ng/ml TNF-a or left untreated for 10 minutes.
The measurement of firefly and Renilla luciferase activities
present in cellular lysates was carried out using the dual-
luciferase reporter assay (Promega, Madison, WI) 24 hours
after adding DNA. Light emission was quantitated using a
Monolight 2010 luminometer (Analytical Luminescence Labo-
ratory, San Diego, CA). Data were presented as firefly lucif-
erase activity normalized by the Renilla luciferase activity
present in each sample, and the values plotted were the
average ± SE of triplicate samples from typical experiments,
which were repeated at least three to five times with nearly
identical results.
Chromatin Immunoprecipitation (ChIP) Assays
ChIP assays were performed using the ChIP Assay Kit
(Upstate Biotechnology, Waltham, MA). Briefly, HN cancer
cells were plated on two 100-mm dishes; cross-linking was
performed by adding formaldehyde directly to a tissue culture
medium to a final concentration of 1% and by incubating for
10 minutes at room temperature; and nuclear extracts were
isolated and sonicated to generate DNA fragments. Tran-
scription factors bound to chromatin were immunoprecipi-
tated with the specific antibody anti-NFnB (C-20; Santa Cruz
Biotechnology, Inc.), protein–DNA cross-linking was re-
versed, and isolated genomic DNA was amplified by PCR,
using specific primers encompassing the NFnB region of the
IL-6 promoter. PCR reactions were performed using 2 ml of a
50-ml DNA extraction in Tris–EDTA buffer with Hi-Fi Taq
polymerase (Invitrogen Life Technologies). PCR mixtures
were amplified for 1 cycle at 94jC for 2 minutes; followed
by 32 cycles at 94jC for 30 seconds, annealing temperature
of 55jC for 30 seconds, and 68jC for 1 minute; and then
subjected to a final elongation at 68jC for 5 minutes. The
primers used were hIL-6P-NFnB-F3 (5V-GCTAGCCTCAAT-
GACGACCT-3V) and hIL-6P-NFnB-R3 (5V-GCCTCAGA-
CATCTCCAGTCC-3V), which amplify 227 bp of the hIL-6
promoter surrounding the NFnB site. hGAPDH (sense: 5V-
CCCCACACACATGCACTTACC-3 V; ant isense: 5 V-
CCTAGTCCCAGGGCTTTGATT-3V), which amplified a frag-
ment with an expected size of 96 bp, served as a control.
Protein Secretion Analysis
CM from stably infectedHNSCCcell lines andHaCaTcells
were prepared by incubating subconfluent cultured cells for
24 hours in DMEMwithout supplements. Harvested CMwere
then filtered through a 0.22-mm low-protein-binding poly-
ethylsulfonate membrane filter. IL-2, IL-5, IL-6, IL-8, IL-10,
IL-12(p70), IL-13, IL-17, GM-CSF, and G-CSF proteins in
the supernatant were assayed by the customized quantita-
tive multiplexed sandwich ELISA Searchlight (Pierce Bio-
technology, Inc.)
Results
HNSCC Cell Lines Constitutively Express IL-6: Correlation
with NFjB Activity
To begin exploring the mechanism(s) responsible for the
elevated IL-6 release from HNSCC, we first examined a
representative set of HNSCC for IL-6 secretion. As shown
in Figure 1A, only a limited amount of IL-6 was found in CM
from an immortalized nontumorigenic epithelial cell line,
HaCaT. In contrast, three representative HNSCC lines,
HN12, HN13, and HN30, secreted remarkable levels of
IL-6. Only one HNSCC from the many cells studied did not
secrete IL-6 to the cultured medium HN6, thus serving as an
internal control. IL-6 mRNA levels paralleled the pattern of
IL-6 secretion in these cells (not shown). Because of the
proposed role of NFnB in IL-6 expression and secretion in
other cellular systems [23], we next determined the activity
of NFnB in these cell lines. Under normal cultured condi-
tions, the nuclear extracts from HN12, HN13, and HN30
cells exhibited constitutively active NFnB activity, as judged
by its ability to bind to NFnB consensus oligonucleotides
Figure 2. Enhanced activity of the IL-6 promoter in HNSCC. A key role for NFjB. (A) Graphic representation of the human IL-6 promoter (IL-6p) and its regulatory
elements depicting their approximate locations relative to the transcription start site (+1). This promoter region includes response elements for the NFjB, AP1, and
helix – loop–helix transcription factors, multiple responsive element, a cAMP-responsive element, and glucocorticoid-responsive element. (B) Site-direct mutations
within the IL-6 promoter. Full-length IL-6pWT and site-direct mutations within the NFjB (DNFjB) andAP1 (DAP1) sites were inserted into the luciferase vector (pGL3-
Luc). Sequences of NFjB (red circle) and AP1 (green circle) transcriptional factor –binding sites and their point mutants (capital letters) are indicated. Full-length IL-6p
WT and its mutants (0.1 g) were transiently transfected into HEK293T cells with p65 (1 g) and the pRL-null construct (0.01 g), and were cultured in serum-free
conditions. Dual-luciferase activity was determined, as described inMaterials andMethods section. Data were presented as firefly luciferase activity normalized by the
Renilla luciferase activity present in each sample, expressed as fold increase relative to control. Values plotted are the average ±SE of triplicate samples from a typical
experiment. (C) The HNSCC cell lines HN13 and HN30, and immortalized keratinocytes (HaCaT) were transiently transfected with pGL3-Luc, pGL3 IL-6p WT and
pGL3 IL-6p-DNFjB, and pGL3 IL-6p-DAP1 (0.3 g), along with the pRL-null construct (0.01 g), and cultured in serum-free conditions. Data are presented as firefly
luciferase activity normalized by the Renilla luciferase activity present in each sample, expressed as fold increase relative to the vector reporter control (pGL3-Luc).
Values plotted were the average ± SE of triplicate samples from a typical experiment that was repeated three to five times with nearly identical results. (D) AP1 activity
in HNSCC. EMSA was performed using a 32P-labeled consensus oligonucleotide containing the sequence for AP1-binding sites. Nuclear extracts were harvested
from serum-deprived cells. Bands (black arrow) represent shifted protein –DNA complexes, which are highly active only in HN13 under regular culture conditions.
HaCaT was also stimulated with TNF-a as a control. (E) In vivo binding of endogenous NFjB to the IL-6 promoter. Chromatin proteins were cross-linked to DNA by
formaldehyde, and purified nucleoprotein complexes were immunoprecipitated by anti-NFjB p65 antibody. The precipitated DNA and total nuclear extracts were
analyzed by PCR for the presence of NFjB IL-6 promoter region corresponding to a fragment of 217 bp (arrow), which was revealed by staining agarose gels with
ethidium bromide. Genomic DNA and TNF-a–stimulated HaCaT were used as a positive control confirming the binding of NFjB to the IL-6 promoter in vivo.
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(Figure 1B), whereas HaCaT and HN6 showed nearly unde-
tectable levels of protein–DNA complexes. As a control, the
treatment of HaCaT and HN6 cells with TNF-a led to en-
hanced NFnB activity. However, only a slight activation was
observed in HN12, HN13, and HN30 on TNF-a stimulation,
aligned with the fact that these cells exhibit elevated levels
of NFnB activity already under basal conditions. To confirm
these observations, we assessed the activity of NFnB in
each cell line. Indeed, as shown in Figure 1C, using an electro-
phoreticmobility shift assay (EMSA),weobserved that nuclear
extracts fromHN12, HN13,HN30, andTNF-a–treatedHaCaT
retarded the mobility of NFnB consensus oligonucleotides in
acrylamide gels. The identity of NFnB in these protein–DNA
complexes was confirmed by the supershift in the apparent
mobility of the complex through the addition of antisera against
the p65 subunit of NFnB (Figure 1C). Thus, the remarkable
secretion of IL-6 in this panel of HNSCC cell lines correlated
with their constitutive activity of NFnB.
Deregulated IL-6 Secretion in HNSCC Cells Correlates
with Enhanced Activity of the IL-6 Promoter: A Role
for the NFjB and AP1 Response Elements
To investigate whether the underlying mechanism leading
to deregulated IL-6 expression involves enhanced tran-
scription from the IL-6 promoter, we inserted the wild-type
(WT) 1.2-kb IL-6 promoter (Figure 2A) and an IL-6 promoter
containing a point mutation in its NFnB response element
(Figure 2B) upstreamof the firefly luciferase gene in the pGL3
reporter plasmid. As a control, we also used an IL-6 pro-
moter, including a point mutant in its AP1 site and in both
NFnB and AP1 sites. When we transfected these constructs
in HEK293T cells, the IL-6 promoter was greatly stimulated
by the coexpression of the p65 NFnB subunit. In contrast,
as expected, the IL-6 promoter harboring a point mutation in
its NFnB site did not respond to p65. Of interest, the AP1-
mutated IL-6 promoter still responded to p65, but the level of
luciferase expression was slightly reduced, suggesting a
potential interaction between these two transcriptional re-
sponse elements.
The reporter plasmids under the control of the WT IL-6
promoter and its mutants were then transiently transfected in
the HNSCC lines. For these experiments, we selected HN13
and HN30 HNSCC cells, as HN12 cells behaved very simi-
larly to HN30, and we used HaCaT cells as controls. When
compared with luciferase expression from the reporter plas-
mid without the IL-6 promoter, HaCaT cells showed a four-
fold activation of the IL-6 promoter. In contrast, HN13 and
HN30 both showed a 16-fold activation of the IL-6 promoter.
Mutations in the NFnB-binding site drastically reduced IL-6
promoter activity in all cell lines, indicating a critical role for
this transcription factor in IL-6 promoter activity. A less
pronounced reduction in IL-6 promoter activity was observed
with the point mutant in the AP1 site, particularly in HN13.
These observations suggested that NFnB is critical for the
activation of IL-6 in all cells, but that, in HN13 cells, AP1 may
cooperate with NFnB to regulate IL-6 expression (Figure 2C).
To examine this possibility, we analyzed the activity of AP1
in HNSCC cell lines by EMSA. AP1 activity was particularly
highly active in HN13 cells, as demonstrated by its ability
to bind to AP1 consensus oligonucleotides, whereas most
cells showed low levels of AP1 protein–DNA complexes. As
a positive control, HaCaT cells showed a high AP1 nuclear
activity on TNF-a stimulation (Figure 2D).
As both NFnB and AP1 were required to stimulate the IL-6
promoter in HN13 cells, we wanted to confirm whether
endogenous NFnB indeed binds to the IL-6 promoter in vivo
in these cells. Therefore, we immunoprecipitated NFnB
cross-linked to chromatin and amplified the human IL-6
promoter using PCR primers surrounding the NFnB-binding
site (ChIP assay). As shown in Figure 2E, whereas PCR
amplification of total genomic DNA from control, HaCaT,
and HN13 cells yielded a fragment of 217 bp, no amplification
was observed in NFnB immunoprecipitates from HaCaT
cells, unless they were stimulated with TNF-a. In contrast,
IL-6 promoter sequences were readily amplified in NFnB
immunoprecipitates from HN13 cells (Figure 2E ), demon-
strating that this transcription factor is constitutively bound
to the IL-6 promoter in vivo.
IKKa and IKK Contribute to p65 Constitutive Activation
in HNSCC
The basal activity of p65 NFnB is repressed by its asso-
ciation with InB, an ankyrin repeat-containing protein that
binds to NFnB and masks its nuclear localization signal, thus
retaining NFnB in its inactive state in the cytosol. The acti-
vation of NFnB involves the phosphorylation of InB on two
serine residues, Ser32 and Ser36, which triggers the rapid
ubiquitination and degradation of phosphorylated InB in the
proteosome, and the consequent nuclear translocation and
activation of NFnB [16]. IKK includes a regulatory subunit,
NEMO (IKKg), and two catalytic kinases subunits, IKKa
(IKK1) and IKKb (IKK2), which are lysates readily detected
from HaCaT, HN12, HN13, and HN30 cells (Figure 3A).
Whereas no phosphorylated IKKa/b could be detected in
HaCaT cells, the levels of phosphorylated (active) IKKa/b
increased dramatically in these cells on TNF-a stimulation
(Figure 3A). In contrast, HN12, HN13, and HN30 showed an
expression of phosphorylated IKKa/b under basal conditions.
To analyze the contribution of IKKs in the constitutive activa-
tion of p65 in these cells, we interfere with endogenous IKKa
and IKKb expression using siRNA. Using the interference in
HN13 as an example, we observed that IKKa- and IKKb-
specific siRNA effectively knocked down the expression of
corresponding kinases without altering the expression of
the untargeted IKK isoform (Figure 3B). Similar results were
obtained in other cell lines (not shown). When siRNA were
transfected into HaCaTcells, the inhibition of IKKa and IKKb
expression drastically reduced p65 activity (P < .001). Sim-
ilarly, the knockdown of these IKKs reduced the activation
of p65 by TNF-a (P < .05) (not shown). Furthermore, the
constitutive activation of NFnB was also repressed in the
HNSCC cell lines HN13 and HN30 by the knockdown of
IKKs, although, in general, the most striking results were
obtained by the interference of IKKb. Indeed, IKKb knock-
down reduced the constitutive activation of p65 in both HN13
(P < .05) and HN30 (P < .01) (Figure 3C).
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Inhibition of NFjB Diminishes IL-6 Promoter Activity
and IL-6 Protein Expression
To further analyze the contribution of NFnB to IL-6 secre-
tion from HNSCC cells, we asked whether interference with
NFnB function affected the production and release of IL-6
from these cells. As both IKKa and IKKb can contribute to
NFnB signaling in HNSCC, and (as previously described)
[24–26] as IKKa and IKKb have unique activities but can
partially compensate for each other’s function, we chose to
explore the role of NFnB through the use of the super re-
pressor InB. The super repressor InB harbors a substitution
of Ser32 and Ser36 for alanine, causing the blockade of InB
proteolysis and, consequently, the sequestration of NFnB in
the cytoplasm, thereby preventing the translocation of NFnB
to the nucleus and its transcriptional activity [16]. Initially,
we observed that this InB repressor inhibited transcription
from an NFnB reporter plasmid in HaCaT cells in a dose-
dependent matter, both under basal conditions or on expo-
sure to TNF-a, using a plasmid encoding the b-galactosidase
gene as a control (Figure 4A). The InB repressor also in-
hibited the activation of the IL-6 promoter by TNF-a in HaCaT
cells (Figure 4B). Similarly, this repressor of NFnB inhibited
the expression of luciferasewhen driven by the isolatedNFnB
response element or the WT IL-6 promoter in both HN13 and
HN30 cells (Figure 4, C and D).
We next engineered lentiviral constructs encoding the IjB
super repressor fused to GFP (Figure 5A) to analyze the
consequences of stably inhibiting NFnB in HNSCC cells. As
depicted in Figure 5B, the protein product of the GFP-IjB
super repressor was readily detected in HaCaTcells infected
with corresponding lentiviruses, using GFP virus as control.
Similarly, these constructs were highly expressed in HNSCC
cells, as visualized by the fluorescent detection of GFPand its
fusion protein (Figure 5, C–F ). As expected, GFP-IjB S32/
36A was restricted primarily to the cytoplasm, whereas GFP
also exhibited strong nuclear distribution. Infection of HNSCC
cells with the lentivirus encoding the super suppressor IjB
S32/36A dramatically diminished the level of IL-6 secreted
in the supernatants of both HN30 and HN13 HNSCC cell
lines, further supporting the notion that NFnB is crucial for
IL-6 promoter activity and protein expression.
Inhibition of NFjB Diminishes Cytokine Release
from HNSCC Cells
As NFnB plays a key role in the regulation of the expres-
sion of numerous inflammatory cytokines, we next explored
the contribution of NFnB to the release of cytokines known to
be expressed in HNSCC cells, in addition to IL-6. Indeed, on
infection with GFP-IjB, we observed a dramatic decrease in
the release of key cytokines from HNSCC cells, including
IL-2, IL-6, IL-8, IL-10, IL-12, GM-CSF, and G-CSF (Figure 6).
Interestingly, there appears to be a more marked inhibition
of certain cytokines in HN13 cells than in HN30 cells, as, for
example, IL-8, IL-12, and GM-CSF were inhibited by less
than 30% in HN30 cells, whereas they were greatly reduced
in HN13 cells.
Inhibition of NFjB Blocks the Autocrine/Paracrine Activation
of STAT3
The remarkable effect of NFnB inhibition on the secretion
of IL-6 and other cytokines from HNSCC cells prompted us to
examine the contribution of NFnB to the potential autocrine/
Figure 3. The role of IKKa and IKK in NFjB regulation in HNSCC cells.
Serum-starved cell lines were immunoblotted with anti-IKKa, IKK, and
phospho-IKKa/ antibodies. Tubulin was used as a loading control (A and B).
(A) HaCaT, HN12, HN13, and HN30 immunoblot analysis shows the level of
expression of IKKa and IKK. Elevated levels of active phospho-IKKa/ in
HN12, HN13, and HN30 cells were detected under basal conditions, using
TNF-a–stimulated HaCaT cells as positive control. (B) A time-course
analysis was performed to assess the effective and selective knockdown of
IKKa and IKK on transfection with their corresponding siRNA. Representa-
tive Western blot analyses depict the expression levels of IKKa/ and tubulin
as loading controls in each cellular lysate. Negative siRNA oligonucleotides
were used as control (C). (C) Nuclear extracts from HaCaT, HN13, and
HN30, with the use of indicated siRNA, were assayed for activated NFjB
levels, as assessed by their ability to bind to a consensus NFjB-binding site
oligonucleotide, and an NFjB–DNA binding complex was revealed by
chemiluminescence on incubation with anti-p65 antiserum followed by a
secondary antibody conjugated to HRP. Bar graphs represent the mean ± SE
of quantitative measurements of NFjB in arbitrary units. Asterisks denote a
significant inhibition of NFjB activity by each specific siRNA interference
(*P < .05, **P < .01, and ***P < .001; analysis of variance and Bonferroni’s
multiple comparison test).
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paracrine activation of the STAT3 signaling pathway in
HNSCC cells. As shown in Figure 7A, inhibition of NFnB did
not affect the expression levels of STAT3 in these cells, but
diminished dramatically the levels of tyrosine-phosphorylated
active STAT3 (pSTAT3Y705). Furthermore, whereas CM from
HN13 and HN30 promote the accumulation of activated
pSTAT3Y705 when added to HaCaT cells, we observed that
the inhibition of NFnB in HN13 and HN30 HNSCC cells
and the consequent reduction in IL-6 and other cytokine
expressions diminished the ability of their CM to activate
STAT3 (Figure 7B).
Nuclear Localization of NFjB Correlates with IL-6
Expression and STAT3 Activation in HNSCC
These findings prompted us to explore whether the acti-
vation status of NFnB correlates with the expression of IL-6
and the phosphorylation of STAT3 in HNSCC tumors using
an immunohistochemical approach. We detected a robust
immunohistochemical stain for p65 in the cytoplasm and the
nucleus (Figure 8A), which is more clearly seen at a higher
magnification (Figure 8B). The nuclear staining of p65 was
present in all areas of the carcinoma, including invading
islands. Indeed, NFnB was present in most of the cases
analyzed (n = 196) (Figure 8F ). pSTAT3Y705 was also ex-
pressed in the majority of tumor cells (Figure 8C). A close-up
view demonstrates the specific nuclear staining of their
phosphorylated form of STAT3 (Figure 8D). IL-6 presented
a generalized cytoplasmic immunoreactivity (Figure 8E ),
which was positive in a large fraction of cases (n = 144)
(Figure 8F ). Immunohistochemical analyses of human
HNSCC tissue array samples demonstrated an excellent
correlation in vivo between the expressions of NFnB, IL-6,
and pSTAT3 in the same tissue tumor cores (Table 1). Indeed,
a significant correlation was present between NFnB and
IL-6 (P V .02), between IL-6 and pSTAT3Y705 (P V .001),
and between NFnB and pSTAT3Y705 (P V .005).
Together, these data are aligned with our observations in
HNSCC cells and support the existence of the autocrine/
paracrine activation of STAT3, which can be initiated by the
NFnB-dependent release of IL-6 and other inflammatory
cytokines from HNSCC cells (Figure 9).
Discussion
A better understanding of the molecular mechanisms under-
lying the development of HNSCC may help identify novel
targets for pharmacological intervention in this disease [27].
In this regard, the nature of signal transduction pathways
Figure 4. Inhibition of NFjB decreases the activity of the IL-6 promoter. HaCaT (A and B) and HNSCC cell lines HN13 (C) and HN30 (D) were transiently
transfected with pNFjB-Luc (0.3 g) (A; 5 in C and D), pIL-6p-Luc (0.3 g) (B; n in C and D), the pRL-null construct (0.01 g), and increased concentrations of
pCEFL IjB S32/36A, and cultured in serum-free conditions. The total amount of plasmid DNA was adjusted to 1 g with pcDNA3--galactosidase. HaCaT was
stimulated with TNF-a (10 ng/ml for 10 min), where indicated (A). Lysates were assayed for dual-luciferase activities. Data were presented as firefly luciferase
activity normalized by the Renilla luciferase activity present in each sample, expressed as fold increase relative to control with only pcDNA3--galactosidase (A and
B) or as percentage (C and D) of the activity without NFjB inhibition by pCEFL IjB S32/36A. Values plotted were the average ± SE of triplicate samples from typical
experiments, which were repeated at least three to five times with nearly identical results.
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whose aberrant activity promotes the unregulated growth
and survival of HNSCC cells has just begun to be elucidated.
These include the overexpression and enhanced phosphor-
ylation of EGFR [10], the elevated activity of the Akt–mTOR
pathway [11,12,28], and the persistent activation of the NFnB
and STAT3 transcription factors [9,29,30]. Whereas EGFR
can stimulate NFnB and STAT3, recent observations indi-
cate that HNSCC can also exhibit EGFR-independent acti-
vation of these key signaling routes [13]. We now show that
the aberrant function of the transcription factor NFnB can
lead to the stimulation of STAT3 by an autocrine/paracrine
mechanism that involves the release of IL-6, thus providing
evidence of the existence of a molecular cross-talk between
the NFnB and STAT3 signaling systems in HNSCC.
IL-6 is a pleiotropic cytokine expressed by a variety of cell
types, including macrophages, fibroblasts, endothelial cells,
T cells, and B cells (reviewed in Oppenheim et al. [31]). It
plays an important role in immune responses, acute-phase
reactions, hematopoiesis, and regeneration, and its produc-
tion is induced by different stimuli, such as T-cell mitogens,
antigenic stimulation, viral infection, and peptide factors, such
as IL-1, TNF-a, IL-2, interferon b, and PGDF [32]. IL-6 is
expressed in psoriatic skin and in cancerous epithelial cells
in HNSCC [33–37]; however, what leads to IL-6 secretion
in human HNSCC is still poorly understood.
The human IL-6 gene, located on chromosome 7p21, is
approximately 5 kb, and its promoter contains important cis-
acting response elements, including NFnB and AP1 sites,
located between nucleotides 75–63 and 286–265 upstream
of the IL-6 mRNA cap site, respectively [38]. In this study,
we found that the high expression of IL-6 in HNSCC cells
correlates with the enhanced activity of the IL-6 promoter,
whereas in certain HNSCC cells, the AP1 transcription factor,
whose activity is associated with malignant transformation
of squamous cell epithelia [39], also contributed partially.
This situation is not unique, as NFnB and AP1 have an addi-
tive effect on the activation of a number of genes associated
with metabolic and inflammatory responses [40,41], which
Figure 5. IL-6 production and secretion are dependent on NFjB activation. Lentiviral vectors were engineered for GFP and the full-length IjB harboring a
substitution of Ser32 and Ser36 for alanine (A, top), which acts as an NFjB super repressor by blocking IjB proteolysis, tagged with a GFP-IjB. The expression
levels of GFP-IjB (B, empty arrow) and GFP (B, black arrow) in HaCaT cells 72 hours after infection with these lentiviruses were documented by immunoblotting
with anti-GFP antibody. Similar results were observed in the HNSCC cell lines HN13 and HN30. GFP-IjB (C and D) and GFP (E) were visualized in vivo in HN13
cells, as well as in HaCaT and HN30 cells (not shown), by fluorescence microscopy at the indicated magnification. High magnification (original magnification, 63)
revealed a cytoplasmatic expression of GFP-IjB (D) and a mostly nuclear expression of GFP (E, inset). After serum starvation, CM from the HNSCC cell lines were
analyzed for IL-6 (F). Data were presented as a percentage of IL-6 secreted in GFP-IjB–expressing cells with respect to GFP-infected controls. Values plotted
were the average ± SE of triplicate samples.
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may enable rapid changes in gene expression in response to
the stimulation of EGFR and the Ras/Raf signal transduction
pathway, which controls AP1 activity [42], in coordination
with proinflammatory cytokines that stimulate NFnB [43]. In
particular, for IL-6 expression, AP1 can cooperate with NFnB,
but the latter appears to have a more prominent and general
role. Indeed, NFnB was found to be bound to the endoge-
nous IL-6 promoter, as judged by chromatin inmmuno-
precipitation assays, and mutations in the NFnB site reduce
IL-6 promoter activity in all HNSCC cells tested. Furthermore,
inhibition of this transcription factor is sufficient to downreg-
ulate IL-6 gene and protein expression. Thus, available evi-
dence suggests that NFnB plays a central role in promoting
IL-6 secretion from HNSCC cells.
Constitutive activation of NFnB is a frequent event in a
variety of neoplasias, including melanoma [44], breast and
prostate carcinoma [45,46], T-cell leukemia [47], Hodgkin’s
and B-cell lymphomas [48,49], multiple myeloma [50], and
HNSCC [29], and the aberrant activity of NFnB has been
shown to contribute to tumor cell survival, proliferation,
migration, and radiation resistance. As previously reported
[51], we observed constitutive NFnB activation in the majority
of HNSCC cells examined, as reflected by the presence of
elevated NFnB DNA-binding activity. The activation of NFnB
in HNSCC depends on IKKa and IKKb activity, as suggested
by knockdown experiments using kinase specific-siRNA.
However, in general, IKKa is less efficient in activating NFnB
B and cannot be substituted by IKKb in animal knockout
studies [24–26,52–54]. Aligned with these observations,
our results suggest that IKKb plays a more prominent role
Figure 6. NFjB-dependent production and secretion of multiple cytokines in HNSCC cells. CM from the HNSCC cell lines HN13 and HN30 stably expressing IjB
S32/36A (GFP-IjB) and GFP were analyzed for the secretion of IL-2, IL-8, IL-10, IL-12, G-CSF, and GM-CSF using a proteomic array. Bar graphs represent the
quantitative measurement of proteins secreted in the CM. Values plotted were the average ± SE of triplicate samples.
Figure 7. Blockade of NFjB inhibits the autocrine/paracrine activation of
STAT3. The HaCaT and HNSCC cell lines HN13 and HN30 were
immunoblotted with anti-pSTAT3Y705 antibody and anti-STAT3. Tubulin was
used as a loading control. (A) Immunoblot analysis shows a decreased level of
active STAT3Y705 inHN13 andHN30 cells stably expressingGFP-IjBS32/36A
with respect to control cells expressing GFP. (B) HaCaT cells were serum-
starved and stimulated for 10 minutes with IL-6 (10 ng/ml), or CM from HN13
and HN30 stably expressing GFP-IjB S32/36A and GFP, or CM from HaCaT
cells (C) as a control. The addition of IL-6 and CM from HN13 and HN30 cells
induces remarkable STAT3 activation (STAT3Y705). The effects of CM on
HN13 and HN30 were prevented by the inhibition of NFjB.
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in NFnB activation in HNSCC tissues. This observation may
facilitate future efforts aimed at elucidating which of the
many molecular events that converge in the phosphorylation
and activation of IKKb are in turn activated in HNSCC cells.
The persistent activation of NFnB can lead to the elevated
expression and secretion of IL-6 in HNSCC, similar to what
was recently described in prostate cancer cells [23]. Further-
more, the transcription factor NFnB also regulates the ex-
pression of other cytokines involved in both inflammatory
and immune responses in HNSCC. In particular, we ob-
served high levels of secretion of IL-2, IL-6, IL-8, IL-10, IL-
12, GM-CSF, and G-CSF, whose expressions were reduced
by NFnB inhibition. Other cytokines were also analyzed,
demonstrating elevated levels of IL-13 followed by lower
levels of IL-5 and IL-17 (data not shown) secreted by HNSCC
Figure 8. NFjB, pSTAT3, and IL-6 are highly expressed in head and neck (HN) clinical samples. Human oral SCC individual samples and tissue arrays were
stained for NFjB p65, pSTAT3Y705, and IL-6. Photographs show representative tumor areas. (A) NFjB is predominantly observed in tumor cells. (B) Cytoplasmatic
and nuclear stainings for NFjB are seen at a higher magnification. (C) pSTAT3Y705 is present in the nucleus of tumor cells. (D) Higher magnification. (E) IL-6 is
strongly expressed in the cytoplasm of tumor cells. (F) The bar graphs summarize the expression of NFjB, pSTAT3Y705, and IL-6 in the HNSCC tissue array. The
number of positive cases is presented as the percentage of tumor tissue samples (n = total number of samples analyzed).
Table 1. Correlation between the Expressions of NFnB, IL-6, and
pSTAT3Y705 in HNSCC [n (%)].





IL-6 8 (6.7) 30 (25.0) V .02 12 (14.3) 18 (21.4) V .001
IL-6+ 4 (3.3) 78 (65) 4 (4.7) 50 (59.6)
NFnB 6 (6.3) 8 (8.3) V .005
NFnB+ 8 (8.3) 74 (77.1)
Cross-Talk between NFnB and STAT3 in Head and Neck Cancer Squarize et al. 743
Neoplasia . Vol. 8, No. 9, 2006
cells. Some of these cytokines have been associated with
increased tumor growth and metastasis, and overall de-
crease of survival [55,56].
IL-6 is readily detected in the serum, tissues, and saliva of
HNSCC patients [36,37,57]; once released, IL-6 secretion
may contribute to HNSCC tumor progression andmetastasis,
as well as to inflammatory and angiogenic responses [58,59]
that characterize this tumor type. An interesting possibility
is that IL-6 secretion may also facilitate the immune evasion
of HNSCC cancer cells. Patients with HNSCC exhibit a
number of functional defects in their tumor-infiltrating and cir-
culating T cells, which may compromise their antitumor im-
mune responses (reviewed in Whiteside [60]). In particular,
recent attention has focused on CD4+ T helper (Th) cells, one
of whose functions is to prime and stimulate the cell-mediated
antitumor immunity initiated byCD8+ cytotoxic T lymphocytes
[61]. In this regard, the release of IL-6 from HNSCC cells can
inhibit the differentiation of CD4+ Th cells into type 1 cells
(which is a subset of CD4+ Th cells that promote the tumor-
icidal activity of CD8+ cytotoxic T lymphocytes) while favoring
the differentiation of CD4+ Th cells into type 2 cells (which
inhibit cell-mediated immune response to tumor cells but
stimulate a less effective humoral response) [62]. The IL-
6– initiated autocrine activation of STAT3 in HNSCC cells
Figure 9. Proposed mechanism of cross-talk between the NFjB and the STAT3 pathways. Constitutive activation of NFjB leads to the production and secretion of
cytokines such as IL-6, which acts on the gp130 cytokine receptor family in an autocrine/paracrine manner and causes the consequent activation of STAT3 in an
EGFR-independent fashion. Inhibition of NFjB by IjB S32/36A diminishes the secretion of those molecules, thereby blocking the activation of the STAT3 pathway.
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may in turn influence the overall pattern of cytokines released
by tumor cells, which can inhibit the maturation and activa-
tion of dendritic cells [63], thus providing an additional mech-
anism that facilitates HNSCC cells to evade the immune
surveillance system.
Remarkably, we observed here that blocking NFnB dimin-
ished the accumulation of active STAT3 in HNSCC cells, thus
suggesting the existence of cross-talk between theNFnB and
the STAT3 pathways through the release of IL-6 and other
cytokines and the autocrine/paracrine activation of cytokine
receptors expressed in HNSCC cells. Indeed, most of the
HNSCCclinical samples that exhibit NFnBalso expressed IL-
6 and exhibited nuclear accumulation of pSTAT3. Only a few
tumors that exhibit pSTAT3 do not show elevated levels of
IL-6 expression, which may represent a subgroup of HNSCC
patients in which the activation of STAT3 is dependent on
EGFR or on another tumor or stromal-released cytokine
[64]. Together, our findings support the emerging view that
a deregulated signaling network, rather than the alteration of
a single biochemical route, underlies the aberrant growth of
HNSCC cells. Conversely, considering that STAT3 is consti-
tutively activated in oral HNSCC (but not in the normal oral
epithelium) [9,10] and that inhibition of STAT3 function leads
to the growth inhibition of HNSCC [65], the observation that
NFnB can in turn enhance the activity of STAT3 in HNSCC
cancer cells may now provide a molecular framework for the
future clinical evaluation of targeting NFnB and/or IL-6 in
HNSCC patients, together with EGFR inhibitors, as a com-
bined treatmentmodality. Thiswould be particularly important
in HNSCC patients displaying elevated local and serum
levels of IL-6, in which their enhanced tyrosine phosphor-
ylation of STAT3 could be resistant to EGFR inhibition.
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